Society News2021-08-27T10:57:04+00:00
14March, 2024

FDA Approved the First CRISPR Treatment – Potential Cure for People with Sickle Cell Disease

March 14th, 2024|Categories: Featured Perspectives On Current Science|

Victoria Gray was diagnosed with sickle cell disease (SCD) when she was just three months old; since then, episodes of pain and frequent hospitalizations have been a part of her life. Many of her dreams seemed like far-off impossibilities when the smallest things, like changing weather, would put her in the hospital. Every four to six weeks, she would ...

21February, 2024

Follow-up Data Confirms That Inclisiran Provides Long-Term Reduction of LDL-Cholesterol

February 21st, 2024|Categories: Featured Perspectives On Current Science|

Cardiovascular disease is the leading cause of death in the United States, exceeding all types of cancer, unintentional injury, and stroke combined. However, updated data from Novartis's open-label trial shows promising long-term results for inclisiran (Leqvio), the first and only small interfering RNA (siRNA) therapy to reduce low-density lipoprotein cholesterol (LDL-C). ORION-8 is part of an extensive clinical trial ...

9February, 2024

The First FDA Approval for a GalNAc-conjugated ASO

February 9th, 2024|Categories: Perspectives on Current Science|

It starts with a pins-and-needle sensation in your feet, or maybe your gastrointestinal tract has become easily irritated, or you've started to lose weight or develop heart problems. Hereditary ATTR amyloidosis can present differently among patients and with symptoms found in far more common diseases, so it is often misdiagnosed. Fortunately, treatment for the disease is expanding, with the ...

23January, 2024

Base Editing in Clinical Trials to Treat Acute Lymphoblastic Leukemia

January 23rd, 2024|Categories: Perspectives on Current Science|

Base editing has experienced a rapid rise in use since it first came on the scene in 2016, with multiple trials underway, testing its ability to treat conditions with precise, single-letter changes to DNA. The technique presents a potentially more accurate and safer method compared to nuclease-based approaches; however, it’s not without its risks. Currently, researchers are investigating how ...

13November, 2023

2023 Annual Meeting Highlights

November 13th, 2023|Categories: Perspectives on Current Science|

We are pleased to note that this year’s annual Oligonucleotide Therapeutics Society meeting in Barcelona, Spain had the highest involvement of any previous meeting, with 800 in-person attendees, 297 abstract submissions, 260 posters, 47 travel grants, 36 Sponsors, and 29 Exhibitors. We hope all who attended in person or virtually enjoyed their time and will carry the passion and ...

5September, 2023

Fanzor: A Programmable RNA-Guided System In Eukaryotes Similar to CRISPR

September 5th, 2023|Categories: Perspectives on Current Science|

Researchers have uncovered the first programmable RNA-guided system in eukaryotes that could be even more precise than CRISPR gene-editing. The discovery — led by Feng Zhang at the McGovern Institute for Brain Research at MIT and the Broad Institute of MIT and Harvard — demonstrates that DNA-modifying proteins exist across all kingdoms of life (1). In a recently published study ...

Go to Top